| Drug Overview | |
|---|---|
| Drug Class | Antimuscarinics |
| Subclass | Competitive Muscarinic Antagonist |
| Primary CV Use | Symptomatic Bradycardia |
| Route | IV / IM / SQ / Ophthalmic |
| Onset (IV) | 1–2 minutes |
| Duration | 30–60 minutes |
| Half-life | ~2–4 hours |
| Metabolism | Hepatic |
| Elimination | Renal |
| Pregnancy | Category C |
| Renal Adjustment | No |
| Hepatic Adjustment | No |
| Black Box Warning | No |
| Controlled | No |
Atropine is a competitive antagonist of muscarinic acetylcholine receptors.
In cardiovascular practice, it is used to treat symptomatic bradycardia by blocking parasympathetic (vagal) tone at the SA and AV nodes.
It increases heart rate by removing inhibitory cholinergic signaling.
Primary Target:
Normal Physiology:
Atropine Effect:
Net Effect:
Cardiovascular:
ACLS:
Other Uses:
Adult (ACLS bradycardia):
Important:
If ineffective:
Absolute:
Relative / Cautions:
Common (anticholinergic effects):
Serious:
Mechanism-based:
Additive anticholinergic effects with:
Bradycardia context / AV node:
Opposite AV nodal effects compared to:
Atropine: